chronic inflammatory demyelinating polyneuropathy (cidP) is the most common treatable chronic neuropathy in the western world. There are three treatment options currently available for cidP: intravenous immunoglobulin, plasma exchange or corticosteroids. despite the efficacy of these therapies cidP patients are often left with permanent neurological deficits, have a poor clinical prognosis or in some cases do not respond to treatment. Furthermore, high cost and restricted availability make them unfeasible in some treatment centres, especially in the developing world. Recent advances in the understanding of the underlying pathogenic mechanisms in cidP have brought a number of novel agents into consideration for use in cidP. Many of these novel therapies have been used in similar autoimmune disorders and target immunopathogenic pathways common to cidP. here we review a number of these novel therapies and their applicability to cidP. Immunopathogenesis cidP is assumed to be an autoimmune disease mediated by humoral and/or cellular immunity against as yet undefined Schwann cell/myelin antigens (see Figure 1) . although the trigger for the autoimmune response is unknown various infectious agents have been implicated in the process but none has been confirmed as a cause of molecular mimicry as in the case of certain subtypes of Guillain-Barre Syndromé.
chronic inflammatory demyelinating polyneuropathy (cidP) is the most common treatable chronic neuropathy in the western world with a prevalence ranging from one to nine cases per 100,000.
1 Typical onset of cidP is between the ages of 30 and 60 years and presents as either a relapsing or progressive, symmetrical neuropathy with proximal and distal weakness which develops over at least 2 months.
2 cidP and its variants comprise group of inflammatory demyelinating diseases of the peripheral nervous system (PNS) in which the immune system mounts an aberrant attack on the nerve. although the majority of patients can be successfully treated with current therapies there remains a considerable proportion that does not respond or are left with permanent disability. here we review current therapies and novel approaches aimed at arresting the underlying immunopathogenic mechanisms of cidP.
Immunopathogenesis
cidP is assumed to be an autoimmune disease mediated by humoral and/or cellular immunity against as yet undefined Schwann cell/myelin antigens (see Figure 1 ). although the trigger for the autoimmune response is unknown various infectious agents have been implicated in the process but none has been confirmed as a cause of molecular mimicry as in the case of certain subtypes of Guillain-Barre Syndromé.
The autoimmune aetiology is supported by studies in both the human disease and animal models in which cell-mediated and humoral mechanisms act synergistically to cause damage to peripheral nerves.
Cellular Mechanisms a variety of infiltrating inflammatory cells can be found in cidP sural
nerve biopsies including cd8+ T cells, cd4+ T cells and macrophages. 3, 4 When autoreactive T cells become activated in the periphery they home to the nerve, adhere to the endothelial cells of endoneurial blood vessels by interacting with adhesion molecules such as
VcaM-1 and icaM-1, roll along the vessel surface and then migrate across the blood nerve barrier (BNB). These activated T cells secrete an array of inflammatory mediators such as matrix metalloproteinases, 5 pro-inflammatory cytokines/chemokines 6,7 and many other molecules which contribute to the permeabilisation of the BNB and upregulation of the immune response within the nerve. Breakdown of the BNB is a critical event as it allows soluble factors such as antibodies access to the endoneurium and can be seen as gadolinium enhancement in MRi of cidP patients. 8, 9 Macrophages are the dominant infiltrating inflammatory cell in cidP nerve and form clusters around endoneurial vessels. 10 in the pathogenesis of cidP. a recent analysis of the T cell repertoire in cidP patients with and without intravenous immunoglobulin (iVig) treatment found a broader activation of cd8+ than cd4+ T cells which was reduced after treatment with iVig.
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There is also evidence that the immunoregulatory cellular response is impaired in cidP patients. 17,18 cd4+cd25highFoxp3+Tregs isolated from cidP patients were less effective in suppressing proliferative responses than those from healthy controls 17 which could contribute to the immune dysfunction seen in cidP.
Humoral Mechanisms
The efficacy of plasma exchange (PE) and iVig in the treatment of cidP indicates that humoral mechanisms are critical to the pathogenesis of cidP. This is supported by the ability of serum from cidP patients 
Current Treatments for Chronic Inflammatory Demyelinating Polyneuropathy
Three standard therapies for cidP have shown efficacy in clinical trials: iVig, plasma exchange and corticosteroids (see Table 1 ).
approximately two-thirds of patients show some clinical improvement after treatment with one of these therapies but the chosen therapy will depend upon availability, cost and patient response and the regime needs be individualised.
Plasma Exchange
Plasma exchange (PE) eliminates soluble factors such as pathogenic antibodies, circulating immune complexes, inflammatory mediators, proinflammatory cytokines and complement from the patient's circulation by taking the blood from the patient and using filtration or centrifugation to remove the plasma. The red blood cells are then re-infused with a plasma substitute which usually consists of human albumin and saline.
Two double blind randomised controlled trials (RcTs) have shown that PE is beneficial in a majority of cidP patients. [38] [39] [40] although the improvement in disability and nerve conduction after treatment with PE can be rapid, it is also short-term and patients often relapse after stopping PE. 41 For stabilisation or maintenance therapy, PE may be combined with another immunosuppressive drug treatment. 42, 43 PE is an invasive therapy and can result in adverse events related to venous access, haemorrhage and haemodynamic changes. These factors and restricted availability have relegated PE to second line therapy in most centres.
Intravenous Immunoglobulin
iVig is used to treat a variety of disorders of the immune system and consists of pooled, polyvalent, serum igG from tens of thousands of donors. The exact mechanisms operating in the treatment of cidP with iVig remain unknown but they are likely to be a combination of many factors. iVig has numerous effects on the immune system including Fc receptor blockade, modulation of Fcγ receptors on effector immune cells, binding of anti-idiotypic antibodies to autoantibodies, neutralisation of complement factors and regulation of various cytokines. 44 Meta-analysis of double-blind RcTs has shown that iVig results in significant improvement of disability lasting 2-6 weeks. 45 Since the benefit is relatively short lived maintenance therapy needs to be given at a frequency to be determined on an individual basis but usually between two-and four times weekly.
The efficacy of iVig was shown to be maintained over 48 weeks when following induction with 1 g/kg over 2-4 days, maintenance dosage of 1 g/kg was given over 1-2 days every three weeks. 46 although the efficacy of iVig has been proven in several RcTs the cost of the treatment is prohibitive and this limits its availability in some developing areas.
Corticosteroids
corticosteroids were the first treatment used for cidP and despite many anecdotal reports over more than 50 years 47 
Novel Future Treatments
While the efficacy of the three main treatments are widely acknowledged there remains a significant proportion of patients, around 30 %, for whom there is no effective treatment. 65 The 
Subcutaneous Immunoglobulin
Subcutaneous immunoglobulin (Scig) was developed for the treatment of those patients with primary immunodeficiency diseases who either experienced unacceptable adverse reactions to iVig or in whom vascular access was difficult. The advantages of Scig over iVig include the ability for patients to administer the treatment at home via a small portable pump, fewer adverse effects and lower cost. 66 a number of studies have been undertaken on the efficacy of Scig in those cidP patients who had previously responded to iVig. in one such study 29 cidP patients who had been undergoing maintenance therapy with iVig self-administered either Scig at a dose corresponding to their equivalent pre-study iVig or subcutaneous saline. 67 after twice-or thrice weekly infusions over 12 weeks, treatment with the SciG resulted in improved isokinetic muscle strength (iKS), grip strength, walking performance and disability score compared with the placebo. Side effects were limited to the injection site and 70 % of the participants preferred to continue with Scig rather than revert to their previous iVig regimen. 67 
Monoclonal Antibodies
The majority of humanised monoclonal antibodies that have been used to treat autoimmune diseases specifically target an individual cell subset, a particular pro-inflammatory mediator such as a cytokine or the general trafficking of immune cells by blocking adhesion molecules. Examples of these strategies are; rituximab which targets the cd20 molecule on B cells and was developed for non-hodgkin's lymphoma, 68 etanercept which targets the cytokine TNFα and was developed for Ra 69 and natalizumab which targets the adhesion molecule α4 integrin was developed for MS.
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Rituximab
Rituximab is an antibody directed against the cd20 molecule expressed by B cells in almost all stages of development from the pre-B cell to later stages of differentiation but is not expressed by plasma cells. it is commonly used to treat B cell lymphoma and rheumatoid arthritis and can reduce inflammatory brain lesions and clinical relapses in relapsing remitting MS. 71 Rituximab use has been analysed in a retrospective, observational, multicentre study of 13 cidP patients who were partial or non-responders to conventional therapy. 72 Nine patients (seven with concurrent haematological diseases) improved clinically or maintained the improvement seen with iVig/PE after a median time of 2 months following the course of rituximab and the effect lasted for up to 1 year. in a similar retrospective, observational, multicentre study of cidP, 110 non-responders to conventional therapy analysed 18 patients who were treated with rituximab. 73 Six of the 18 patients responded to rituximab showing at least a one point improvement on the Rankin scale. a number of case studies have reported on the efficacy of rituximab treatment in cidP when there is a co-existent B cell disease such as idiopathic thrombocytopaenic purpura, 74 SlE75 and Morvan syndrome and myasthenia gravis 76 and it appears that treatment with rituximab benefits those with concomitant haematological disease more than those with idiopathic cidP. and multiple sclerosis 80, 81 and a small number of iVig-dependent cidP patients reported in a retrospective study. 82 Seven patients in whom immunomodulatory therapy had failed to decrease the interval between iVig infusions were given alemtuzumab and followed for an average of 785 days. after treatment with alemtuzumab monthly iViG use was reduced by 26 % and the administration interval increased from 22 to 136 days. 82 Two patients had a long remission, two had a partial response and there was no obvious benefit in the remaining three patients. however, three patients developed autoimmune disease after treatment -a well documented side effect of alemtuzmab use.
Eculizumab
Eculizumab is a humanised monoclonal antibody directed towards the human complement factor c5 and has been used to treat the complement mediated lysis of red blood cells in paroxysmal nocturnal haemoglobinuria. 83 Binding of eculizumab to c5 prevents terminal complement activation and the subsequent formation of the membrane attack complex and cell lysis. although eculizumab has not been tested in cidP it has been used in an open-label study in multifocal motor neuropathy (MMN) patients to assess safety and tolerability in combination with iVig. 84 Treatment with eculizumab in combination with iVig was well tolerated and safe but there 
Etanercept
Etanercept is a TNF-α antagonist that is commonly used to treat Ra and psoriasis. in an uncontrolled, retrospective study of 10 cidP patients treated with etanercept three improved, three had possible improvement and two worsened after treatment. 86 While etanercept may be effective in some cidP patients it has also been associated with the development of demyelinating neuropathy in patients taking it for other conditions 87, 88 and exacerbations of multiple sclerosis.
Fingolimod (FTY720)
Fingolimod is a sphingosine-1-phosphate (S1P) receptor modulator that binds to S1P receptors on lymphocytes. 89 Binding of fingolimod to the S1P receptor causes lymphocytes to be sequestered in the secondary lymphoid organs preventing their migration to sites of inflammation. 90 Fingolimod is an oral formulation that has been 
